Filter by
Format
All
Sort by
Newest

Metabolic

  • Empagliflozin
  • Linagliptin
  • Glyxambi
/sg/metabolic/empagliflozin/voice-of-crm/how-are-crm-conditions-linked

3:04
VoCRM||How are CRM conditions linked?
/sg/metabolic/empagliflozin/lets-talk/what-are-kidney-benefits-empagliflozin-can-offer-heart-failure-patients

3:01

PTPHF||What are the kidney benefits that empagliflozin can offer to heart failure patients?
/sg/metabolic/empagliflozin/lets-talk/what-makes-sglt2i-ideal-hf-therapy

3:54

PTPHF||What makes SGLT2i an ideal HF therapy?
/sg/metabolic/empagliflozin/lets-talk/what-role-empagliflozin-patients-hospitalized-heart-failure

4:28

PTPHF||What is the role of empagliflozin in patients hospitalized for heart failure?
/sg/metabolic/empagliflozin/lets-talk/what-do-we-know-about-consistency-results-empagliflozin-across-spectrum-ejection

2:52

PTPHF||What do we know about the consistency of the results for empagliflozin across the spectrum of ejection fraction?
/sg/metabolic/empagliflozin/lets-talk/what-impact-treatment-landscape-early-benefits-seen-emperor-trials

2:27
PTPHF||What is the impact on the treatment landscape from the early benefits seen in the EMPEROR trials?
/sg/metabolic/empagliflozin/lets-talk/what-impact-sglt-2i-trials-hfpef

5:42

PTPHF||What is the impact of SGLT-2i trials in HFpEF?
/sg/metabolic/empagliflozin/lets-talk/how-has-hfpef-guidelines-evolved-advent-sglt2i-trials

4:22

PTPHF||How has the HFpEF guidelines evolved with the advent of SGLT2i trials?
/sg/metabolic/empagliflozin/lets-talk/guidelines-recommend-4-pillar-approach-managing-hfref-what-practical-approach

4:25

PTPHF||Guidelines recommend the 4-pillar approach in managing HFrEF. What is a practical approach to implement this?
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/empa-kidneys-further-results-on-annual-rate-of-change-in-egfr

EK22||EMPA-KIDNEY's Further Results on Annual Rate of Change in eGFR
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/ero-renal-data-analysis-asian-patients

2:57
RCJ||ERO Renal Data - Analysis in Asian patients
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/why-dedicated-renal-outcomes-study-impt-prof-groop-video

0:54
RCJ||Why a dedicated renal outcomes study is impt - Prof Groop video
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/how-empa-kidney-trial-different-other-dedicated-slgt2i-kidney-trials

2:08
RCJ||How EMPA KIDNEY trial is different from other dedicated SLGT2i kidney trials - Prof Groop
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/how-could-ero-impact-way-we-treat-patients-ckd-prof-groop

0:59
RCJ||How could ERO impact the way we treat patients with CKD - Prof Groop
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/which-academic-body-conducting-empa-kidney-study-prof-groop

0:42
RCJ||Which academic body is conducting the EMPA-KIDNEY study - Prof Groop
/sg/resources/metabolic/webinar-3-hand-hand-against-heart-failure

1:30:30

Webinar 3: Hand in hand against heart failure
/sg/resources/metabolic/webinar-2-lets-look-our-patients

1:23:35

Webinar 2: Let's look at our patients!
/sg/metabolic/empagliflozin/tools-apps/2022-ada-standard-care

2022 ADA Standard of Care
/sg/metabolic/empagliflozin/tools-apps/stay-connected-patient-material

Stay Connected Patient Material
/sg/metabolic/empagliflozin/tools-apps/jardiance-patient-initiation-guide

JARDIANCE Patient Initiation Guide
/sg/metabolic/empagliflozin/tools-apps/prof-wu-empagliflozin-cuts-insulin-need-patients-t2d

2:03
Prof Wu: "Empagliflozin cuts Insulin Need in Patients with T2D"
/sg/metabolic/empagliflozin/tools-apps/prof-verma-esc-guidelines-2019-managing-t2d-cv-risk-changing-perspective-sglt2i

7:22
Prof Verma: "ESC guidelines 2019- Managing T2D with CV Risk, Changing Perspective with SGLT2i"
/sg/metabolic/empagliflozin/tools-apps/prof-ted-wu-t2d-patients-a1c-well-controlled-and-high-cv-risk-would-you-add

2:19
Prof Ted Wu: "T2D Patients with A1c Well-controlled and High CV Risk, Would you Add Empagliflozin and Why?"
/sg/metabolic/empagliflozin/tools-apps/prof-verma-burden-heart-failure-t2d-how-empagliflozin-helps

6:51
Prof Verma: "Burden of Heart Failure in T2D, how Empagliflozin Helps?"
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/empagliflozin-cardio-renal-metabolic-benefits

1:47
Empagliflozin Cardio Renal Metabolic Benefits
/sg/metabolic/empagliflozin/tools-apps/25th-feb-ropu-webinar

1:45:38
The Power to Accomplish More
/sg/metabolic/empagliflozin/tools-apps/metabolism-jardiance-esc-easd-guideline-infographic

Metabolism Jardiance- ESC-EASD Guideline Infographic
/sg/metabolic/empagliflozin/tools-apps/sgjardiance-videoprof-ricardo-fontes-carvalho

1:40
SG_Jardiance Video_Prof Ricardo Fontes Carvalho
/sg/metabolic/empagliflozin/prescribing-information/empagliflozin-metfromin-hcl-jardiance-duo-prescribing-information

Empagliflozin + Metfromin HCl (Jardiance Duo®) Prescribing Information
/sg/metabolic/empagliflozin/prescribing-information/empagliflozin-jardiance-prescribing-information

Empagliflozin (Jardiance®) Prescribing Information
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/5-years-empa-reg-outcome-journey

5 years EMPA-REG OUTCOME Journey
/sg/metabolic/empagliflozin/when-time-meets-power/wtmp-25-years-possibilities-dda

0:40
WTMP 2.5 Years of possibilities DDA
/sg/metabolic/empagliflozin/cv-risk-protection/emprise®-new-data-release-ada-congress-2020

EMPRISE® New Data Release in ADA Congress 2020
/sg/metabolic/empagliflozin/cv-risk-protection/emprise-empagliflozin-real-world-effectiveness

EMPRISE - Empagliflozin Real World Effectiveness
/sg/respiratory/spiolto/respimat/how-use

00:51
Preparing Respimat® for Daily Use
/sg/metabolic/linagliptin/simplicity/advances-linagliptin-has-brought-t2d-care

3:56
Advances That Linagliptin Has Brought to T2D Care
/sg/metabolic/linagliptin/carmelina/spotlight-carmelina

2:22
Spotlight on CARMELINA
/sg/metabolic/linagliptin/efficacy/spotlight-efficacy-data

1:26
Spotlight on efficacy data
/sg/metabolic/linagliptin/efficacy/spotlight-efficacy-broad-range-patients

4:16
Spotlight on efficacy in a broad range of patients
/sg/metabolic/linagliptin/simplicity/linagliptin-helps-simplify-management-t2d

1:29
Linagliptin helps simplify the management of T2D
/sg/metabolic/linagliptin/simplicity/defining-simplicity-clinical-practice

6:06
Defining Simplicity in Clinical Practice
/sg/metabolic/linagliptin/carolina/spotlight-carolina

2:33
Spotlight on CAROLINA
/sg/metabolic/linagliptin/convenience/carmelina-and-carolina-extensive-dataset-unique-cvot-programme

0:36
CARMELINA and CAROLINA: An extensive dataset from a unique CVOT programme.
/sg/metabolic/linagliptin/carmelina/spotlight-carmelina-safety

0:48
Spotlight on CARMELINA Safety
/sg/metabolic/linagliptin/convenience/spotlight-safety-data

0.20
Spotlight on safety data
/sg/metabolic/linagliptin/simplicity/10-years-simplicity-trajenta

1:59
10 years of Simplicity with Trajenta
/sg/metabolic/linagliptin/carmelina/robust-cvot-program-carmelina

1:52
Robust CVOT program - CARMELINA
/sg/metabolic/linagliptin/carolina/robust-cvot-program-carolina

2:03
Robust CVOT program - CAROLINA
/sg/metabolic/linagliptin/prescribing-information/trajenta-duo-prescribing-information

Linagliptin + Metformin HCl (Trajenta Duo®) Prescribing Information
/sg/metabolic/linagliptin/prescribing-information/trajenta-prescribing-information

Linagliptin (Trajenta®) Prescribing Information
/sg/metabolic/glyxambi/tool-apps/for-your-practice/addressing-core-defects-t2d-powerful-glycemic-control

2:14
ADDRESSING THE CORE DEFECTS OF T2D FOR POWERFUL GLYCEMIC CONTROL
/sg/metabolic/glyxambi/tool-apps/for-your-practice/benefits-early-intensification

1 Benefits of Early Intensification
/sg/metabolic/glyxambi/tool-apps/for-your-practice/2-proven-diabetic-medications

2 Proven Diabetic Medications
/sg/metabolic/glyxambi/tool-apps/for-your-practice/3-convincing-cvots

3 Convincing CVOTs
/sg/oncology/giotrif/efficacy/pre-clinical-and-clinical-activity-giotrif-uncommon-egfr-mutations

GIOTRIF® in uncommon EGFR mutations
/sg/oncology/giotrif/efficacy/sequential-treatment-afatinib-and-osimertinib-patients-egfr-mutation-positive-non-small

Publication: GioTag
/sg/oncology/giotrif/safety/management-giotrif-adverse-events-real-world

SEREAL||Management of GIOTRIF® adverse events in the real world
/sg/oncology/giotrif/safety/strategies-optimise-management-egfr-tki-related-side-effects

Strategies to optimise the management of EGFR  TKI-related side effects

Oncology

  • Afatinib
/sg/oncology/giotrif/sequencing/real-world-effectiveness-sequential-giotrif-osimertinib-toast-publication

3:57
RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - TOAST Publication
/sg/oncology/giotrif/efficacy/real-world-effectiveness-giotrif-vs-osimertinib-data-japan

3:01
RWDRI||Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan
/sg/oncology/giotrif/efficacy/real-world-effectiveness-giotrif-brain-metastases-data-korea-and-taiwan

2:37
RWDRI||Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan
/sg/oncology/giotrif/sequencing/real-world-effectiveness-sequential-giotrif-osimertinib-data-giotag-and-reset-studies

2:20
RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - Data from GIOTAG and RESET studies
/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-gioswing-sequential-cohort-combined-analysis

SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies)
/sg/oncology/giotrif/sequencing/totality-outcome-of-afatinib-giotrif-sequential-treatment-in-patients-with-egfrm-nsclc

Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC
/sg/oncology/giotrif/efficacy/south-korean-dataset-frontline-giotrif-uncommon-egfr-mutations

South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
/sg/oncology/giotrif/expert-conversations/webinar-series/taking-cancer-webinar-lets-toast-maximising-time-egfr-tki-therapy-qa

00:00
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)
/sg/oncology/giotrif/expert-conversations/webinar-series/taking-cancer-webinar-lets-toast-maximising-time-egfr-tki-therapy-lecture

00:00
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)
/sg/oncology/giotrif/sequencing/totality-outcome-afatinib-giotrif-sequential-treatment-patients-egfrm-nsclc

Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC (CNS cohort)
/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-upswing-sequential-cohort

SEREAL||GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort
/sg/oncology/giotrif/efficacy/giotrif-safety-and-effectiveness-real-world

SEREAL||GIOTRIF® safety and effectiveness in the real world
/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-japan

SEREAL||Real-world evidence: GIOTRIF® in Japan
/sg/oncology/giotrif/expert-conversations/webinar-series/esmo-asia-2021-strategic-approach-select-and-sequence-therapies-egfrm-nsclc

28:44
ESMO Asia 2021 – A Strategic Approach to Select and Sequence Therapies in EGFRm+ NSCLC
/sg/oncology/giotrif/expert-conversations/webinar-series/esmo-asia-2021-role-egfr-tkis-treatment-squamous-nsclc

12:56
ESMO Asia 2021 – The Role of EGFR-TKIs in the Treatment of Squamous NSCLC
/sg/oncology/giotrif/expert-conversations/webinar-series/esmo-asia-2021–tackling-uncommon-egfr-mutations

13:45
ESMO Asia 2021 – Tackling Uncommon EGFR Mutations
/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-taiwan

Real-world evidence: GIOTRIF® in Taiwan
/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-south-korea-reset-study

GIOTRIF® followed by 3rd generation TKI in RESET study
/sg/oncology/giotrif/expert-conversations/webinar-series/6th-sso-asm-lung-track-evolving-treatment-landscape-egfrm-nsclc

00:00
6th SSO ASM Lung Track – Evolving Treatment Landscape in EGFRm+ NSCLC
/sg/oncology/giotrif/efficacy/giotrif-efficacy-and-safety-elderly-egfrm-nsclc-patients

GIOTRIF® in elderly
/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-efficacy-taiwan-and-korea

GIOTRIF® RWE in uncommon EGFR mutations
/sg/oncology/giotrif/efficacy/south-korea-real-world-data

GIOTRIF® RWE in South Korea
/sg/oncology/giotrif/dosing-and-administration/giotrif-maintains-efficacy-despite-dose-modification

GIOTRIF® maintains efficacy despite dose modification
/sg/oncology/giotrif/safety/ae-management-focus-paronychia

AE management in focus: Paronychia
/sg/oncology/giotrif/safety/ae-management-focus-skin-rash

AE management in focus: Skin Rash
/sg/oncology/giotrif/efficacy/real-world-retrospective-study-suggests-giotrif-viable-2nd-line-treatment-option

GIOTRIF® in SqCC
/sg/oncology/giotrif/efficacy/giotrif-delays-median-time-cns-progression-versus-chemotherapy

SEREAL||Impact of GIOTRIF® in delaying CNS progression
/sg/oncology/giotrif/efficacy/giotrif-treatment-nsclc-harbouring-uncommon-egfr-mutations-published-pooled-analysis-693

SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients
/sg/oncology/giotrif/efficacy/giotrif-real-world-data-patientss-cns-involvement

SEREAL||GIOTRIF® RWE in patients with brain metastases
/sg/oncology/giotrif/efficacy/taiwan-real-world-data

SEREAL||GIOTRIF® RWE in Taiwan
/sg/oncology/giotrif/efficacy/consistent-efficacy-giotri-observed-across-real-world-studies

SEREAL||GIOTRIF® efficacy in the real-world
/sg/oncology/giotrif/efficacy/giotrif-significantly-reduces-relative-risk-disease-progression-or-death-vs-gefitinib

SEREAL||GIOTRIF® in LUX-Lung 7
/sg/oncology/giotrif/efficacy/giotrif-potency-and-specificity-against-egfr-mutations

GIOTRIF® in common EGFR mutations
/sg/oncology/giotrif/dosing-and-administration/results-realgido-global-real-world-study

SEREAL||RealGiDo: Impact of GIOTRIF® dose adjustment in the real-world setting
/sg/oncology/giotrif/japan-real-world-evidence-supports-sequential-treatment-use-upfront-2nd-generation-tki

SEREAL||GIOTRIF® sequential RWE in Japan
/sg/oncology/giotrif/giotag-1st-global-study-show-feasibility-sequential-therapy-giotrif-followed-osimertinib

SEREAL||GioTag sequence may delay time to chemotherapy
/sg/oncology/giotrif/post-hoc-analyses-lux-lung-trials-giotrifr-followed-3rd-generation-tki

SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Impact on OS)
/sg/oncology/giotrif/uptake-subsequent-therapy-lux-lung-3-6-and-7

SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Uptake rate)
/sg/oncology/giotrif/efficacy/first-line-giotrif-data-over-30-real-world-studies-date

GIOTRIF® real world experience in Asia
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/latest-advances-treating-part3

10:55
Latest advances in treating advanced NSCLC with driver mutations - Part3
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/latest-advances-treating-part2

20:39
Latest advances in treating advanced NSCLC with driver mutations - Part2
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/latest-advances-treating-part1

22:36
Latest advances in treating advanced NSCLC with driver mutations - Part1
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/latest-advancement-lung-cancer-part3

18:12
Latest advancement in Lung Cancer Clinical Research - Part3
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/latest-advancement-lung-cancer-part2

42:37
Latest advancement in Lung Cancer Clinical Research - Part2
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/latest-advancement-lung-cancer-part1

36:29
Latest advancement in Lung Cancer Clinical Research - Part1
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/resistance-mechanisms-part-3

21:11
Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSCLC - Part 3
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/resistance-mechanisms-part-2

36:25
Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSCLC - Part 2
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/resistance-mechanisms-part1

44:41
Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSCLC - Part 1
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/biomarker-detection-lung-cancer-part3

8:14
Biomarker Detection in Lung Cancer: The Pros and Cons of Multiplex Testing - part3
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/biomarker-detection-lung-cancer-part2

23:12
Biomarker Detection in Lung Cancer: The Pros and Cons of Multiplex Testing - part2
/sg/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/biomarker-detection-lung-cancer

20:53
Biomarker Detection in Lung Cancer: The Pros and Cons of Multiplex Testing - Part 1
/sg/oncology/giotrif/efficacy/afatinib-treatment-nsclc-harbouring-uncommon-egfr

2:40
Video: Uncommon EGFR pooled analysis in 693 patients
/sg/oncology/giotrif/expert-conversations/lecture-series/a-real-world-experience

19:15
Effectiveness of Dose Modification Strategies with Afatinib: A Real-World Experience
/sg/oncology/giotrif/expert-conversations/lecture-series/egfr-tki-related-dermatological-adverse

21:28
EGFR TKI-related Dermatological Adverse Events
/sg/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive-video

3:05
Video: GioTag Final Analysis
/sg/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive

Publication: GioTag Final Analysis
/sg/oncology/giotrif/efficacy/giotrif-delays-onset-risk-cns-progression

GIOTRIF® delays onset and risk of CNS progression in patients with or without brain metastases
/sg/oncology/giotrif/efficacy/giotrif-vs-gefitinib-1st-line-treatment-egfrm-nsclc

GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
/sg/oncology/giotrif/efficacy/giotrif-provides-3-years-long-term-response

GIOTRIF® provides ≥3 years long-term response even with dose modification
/sg/oncology/giotrif/safety/xerosis-management

AE management in focus: Xerosis
/sg/oncology/giotrif/safety/stomatitis-management

AE management in focus: Stomatitis
/sg/oncology/giotrif/safety/scalp-lesion-management

AE management in focus: Scalp lesion
/sg/oncology/giotrif/safety/ae-management-focus-diarrhoea

AE management in focus: Diarrhoea
/sg/oncology/giotrif/sequencing/sequential-treatment-afatinib

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell-lung cancer: an observational study
/sg/oncology/giotrif/prescribing-information

Afatinib (Giotrif®) Prescribing Information

Respiratory

  • Tiotropium + Olodaterol
/sg/respiratory/spiolto/respimat/respimat-delivers-drug-actively

03:29
Respimat delivers drug actively without the need of COPD patients to forcefully inhale
/sg/respiratory/spiolto/guidelines/gold-2019-role-lama-laba

01:49
GOLD 2019 - Role of LAMA/LABA
/sg/respiratory/spiolto/guidelines/gold-update-2019

08:30
GOLD Update 2019
/sg/respiratory/spiolto/tovito/tovito-phase-iii-clinical-trial-programme

TOVITO® Clinical Trial Programme
/sg/respiratory/spiolto/respimat/importance-particle-size

01:17
Respimat® produces a soft mist of high fine particle fraction aerosol which delivers Spiolto® deep into patients' lungs
/sg/respiratory/spiolto/respimat/how-assemble

01:23
Respimat® Device Assembly - Preparation for First Use
/sg/respiratory/spiolto/efficacy/treatment-lamalaba-vs-lamalabaics

02:02
WISDOM trial suggests only a minority of COPD patients benefit from the addition of an ICS on top of SPIRIVA+LABA, and these are clearly identifiable
/sg/respiratory/spiolto/efficacy/treatment-lamalaba-vs-labaics

01:35
ENERGITO and FLAME demonstrate consistent superiority with LAMA/LABA vs LABA/ICS for all outcomes related to lung function, symptom control and exacerbations
/sg/respiratory/spiolto/efficacy/early-intervention-optimize-lung-function

02:13
Early intervention to optimize lung function
/sg/respiratory/spiolto/prescribing-information

Spiolto® Respimat® Prescribing Information

Cardiovascular

  • Telmisartan
  • Dabigatran etexilate
/sg/cardiovascular/telmisartan/video/cv-protection-benefits

0:49
What is the edge of Telmisartan over other ARBs in terms of molecular structure?
/sg/cardiovascular/telmisartan/video/delta-lock-structure

1:24
CV Protection Benefits
/sg/cardiovascular/telmisartan/video/what-edge-telmisartan-over-other-arbs-terms-molecular-structure

1:24
Delta Lock Structure
/sg/cardiovascular/dabigatran-etexilate/patient-materials/patient-alert-card

Patient Alert Card
/sg/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-praxbind

Prescribing Information for Praxbind®
/sg/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-pradaxa

Prescribing Information for Pradaxa®

Inflammation

  • Nintedanib
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/identifying-ild-patients-ra-dr-anna-hoffman-vold

4:17

A1-R101||A2-R101||Identifying ILD in patients with RA by Dr. Anna Hoffman-Vold
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/ra-ild-delphi-consensus-screening-algorithm

A1-R101||A2-R101||RA-ILD DELPHI CONSENSUS SCREENING ALGORITHM
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/how-identify-patients-ra-ild-who-can-benefit-ofev

A1-R101||A2-R101||How to identify patients with RA-ILD who can benefit from OFEV
/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-ppf-diagnosis-and-treatment-atsersjrsalat-guideline

FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline
/sg/inflammation/nintedanib/expert-view/recent-developments-management-ild-dr-felix-chua-royal-brompton-hospital

24:26

FSIN||Recent developments in the management of ILD - Dr Felix Chua (Royal Brompton Hospital)
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/how-recognize-ild-ppf-patients-ctd

FSIN||How to recognize ILD in PPF patients with CTD
/sg/inflammation/nintedanib/expert-view/side-effect-management-adherence-panel-discussion-dr-nicole-goh-ms-charlotte-ild-nurse

28:58
FSIN||Side effect management & adherence (Panel discussion) - by Dr Nicole Goh, Ms Charlotte (ILD Nurse), Dr Felix, Dr Voon
/sg/inflammation/nintedanib/efficacy/inbuild-trial-efficacy-autoimmune-ild-patients

SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients)
/sg/inflammation/nintedanib/efficacy/inbuild-trial-population-and-baseline-medications

SGOFV2023COM||INBUILD® Trial Population and Baseline Medications
/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-focus-autoimmune-ilds

Progressive Pulmonary Fibrosis: focus on autoimmune ILDs
/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-diagnosis-treatment-atsersjrsalat-guideline

Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/importance-prompt-treatment-ipf

The Importance of Prompt Treatment of IPF
/sg/inflammation/nintedanib/expert-view/managing-risks-bleeding-myocardial-infarction-dr-steve-yang

4:40
SGOFV2022COM||Managing Risks of Bleeding & Myocardial Infarction with Dr. Steve Yang
/sg/inflammation/nintedanib/efficacy/key-managing-progression-ssc-ild-patients

SGOFV2022COM||The key to managing progression in SSc-ILD patients
/sg/inflammation/nintedanib/expert-view/meet-expert-dr-oliver-distler-key-summary-video

8:36
A2-R101||Meet-the-Expert with Dr. Oliver Distler: Key Summary Video
/sg/respiratory/ofev/about-pulmonary-fibrosis/ra-ild-patient-profile-julie

A1-R101||A2-R101||RA-ILD Patient Profile - Julie
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/ssc-ild-patient-profile-stephanie

A1-R101||A2-R101||SSc-ILD Patient Profile - Stephanie
/sg/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-drvsmith

A2-R101||Rheum MTE – Management Strategies Key highlights -Dr. V. Smith
/sg/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-dr-oliver-distler

A2-R101||Rheum MTE – Management Strategies Key highlights -Dr. Oliver Distler
/sg/inflammation/nintedanib/expert-view/expert-videos-ssc-ild-management-chapter-5

2:34
A1-R101||A2-R101||Expert Videos on SSc-ILD Management - Chapter 5
/sg/inflammation/nintedanib/expert-view/expert-videos-ssc-ild-management-chapter-2

3:58
A1-R101||A2-R101||Expert Videos on SSc-ILD Management - Chapter 2
/sg/inflammation/nintedanib/expert-view/ppf-guideline-prof-toby-maher

1:29
A1-R101||A2-R101||PPF Guideline - Prof Toby Maher
/sg/inflammation/nintedanib/mechanism-action/ctd-ild-pathophysiology-moa

4.41
A1-R101||CTD-ILD Pathophysiology & MoA
/sg/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-dr-anna-maria-hoffmann-vold

A2-R101||Rheum MTE – Management Strategies Key highlights - Dr. Anna Maria Hoffmann-Vold
/sg/inflammation/nintedanib/mechanism-action/experts-video-ild-management

4:41
A2-R101||Experts Video on ILD Management
/sg/inflammation/nintedanib/expert-view/managing-gastrointestinal-side-effects-dr-steve-yang

3:16
Managing gastrointestinal side effects with Dr. Steve Yang
/sg/inflammation/nintedanib/efficacy/why-should-ssc-ild-patients-be-treated-early

Why should SSc-ILD patients be treated early?
/sg/inflammation/nintedanib/expert-view/importance-early-ssc-ild-diagnosis

4:16
A1-R101||A2-R101||Expert Videos on SSc-ILD Management - Chapter 1
/sg/inflammation/nintedanib/expert-view/managing-liver-enzyme-elevations-dr-steve-yang

3:50
Managing liver enzyme elevations with Dr. Steve Yang
/sg/inflammation/nintedanib/efficacy/acute-exacerbations-ilds-and-role-ofev

Acute Exacerbations of ILDs and the Role of OFEV®
/sg/inflammation/nintedanib/expert-view/meet-expert-dr-hoffmann-vold-key-summary-video

5:20
A2-R101||Meet-the-Expert with Dr. Hoffmann-Vold: Key Summary Video
/sg/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-droliver-distler

Meet-the-Expert with Dr. Oliver Distler: Highlights Report
/sg/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-dramhoffmann-vold

Meet-the-Expert with Dr. Hoffmann-Vold: Highlights Report
/sg/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-drvsmith

Meet-the-Expert with Dr. Vanessa Smith: Highlights Report
/sg/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-drmaringer

Meet-the-Expert with Dr. Martin Aringer: Highlights Report
/sg/inflammation/nintedanib/expert-view/prof-martin-kolb-why-early-detection-and-intervention-important-ild

2:19
With Prof Martin Kolb: Why is early detection and intervention important in ILD?
/sg/inflammation/nintedanib/expert-view/dse-ee-video-monitoring-progression

2:04

DSE EE Video: Monitoring for Progression
/sg/inflammation/nintedanib/expert-view/what-systemic-sclerosis-associated-ild-and-importance-treating-pulmonary-fibrosis-af

2:47

What is Systemic Sclerosis associated with ILD (and importance of treating Pulmonary Fibrosis with AF)
/sg/inflammation/nintedanib/expert-view/richeldi-maher-video-early-use-anti-fibrotics-and-benefits-patients

0:57

Richeldi & Maher Video: Early Use of Anti-Fibrotics and the benefits to patients
/sg/inflammation/nintedanib/expert-view/3rd-indication-approval-ofev-paradigm-shift-treatment-pf-ild-qa

13:05
3rd Indication Approval for OFEV® - A Paradigm Shift in the Treatment of PF-ILD (Q&A)
/sg/inflammation/nintedanib/expert-view/3rd-indication-approval-ofev-paradigm-shift-treatment-pf-ild-lecture

1:49:27
3rd Indication Approval for OFEV® - A Paradigm Shift in the Treatment of PF-ILD (Lecture)
/sg/inflammation/nintedanib/efficacy/3rd-indication-approval-ofev-paradigm-shift-treatment-pf-ild

2:30
3rd Indication Approval for OFEV® - A Paradigm Shift in the Treatment of PF-ILD
/sg/inflammation/nintedanib/safety/listen-our-experts-summarise-safety-profile-ofev-inbuild

2:12
INBUILD® Trial Safety
/sg/inflammation/nintedanib/efficacy/ofev-reduces-risk-acute-exacerbations-seen-inbuild

3:12
INBUILD® Trial Efficacy (Acute Exacerbations)
/sg/inflammation/nintedanib/efficacy/ofev-first-and-only-approved-therapy-pf-ild

2:03
INBUILD® Trial Efficacy (FVC)
/sg/inflammation/nintedanib/efficacy/listen-our-experts-share-their-insights-why-inbuild-important-study-patients-pf-ild

2:33
INBUILD® Trial Introduction
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/discover-common-link-interstitial-lung-diseases

3:05
Pathophysiology of Pulmonary Fibrosis in ILD
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/listen-our-experts-share-their-thoughts-what-pf-ild-and-high-unmet-need-surrounding-disease

2:30
Progressive Fibrosing ILD
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/listen-our-experts-explain-importance-proactive-monitoring-patients-ild

2:04

Monitoring for Progression
/sg/inflammation/nintedanib/prescribing-information/nintedanib-ofev-prescribing-information

Nintedanib (Ofev®) Prescribing Information
/sg/inflammation/nintedanib/expert-view/learn-experts-why-it-important-reduce-ae-ipf

2:05
Intepreting acute exacerbations data with Prof. Luca Richeldi and Prof. Toby Maher
/sg/inflammation/nintedanib/mechanism-action/ofevr-inhibits-fundamental-pathways-fibrosis

02:48
SGOFV2023COM||OFEV® MOA in SSc-ILD
/sg/inflammation/nintedanib/mechanism-action/approved-anti-fibrotic-known-and-established-mechanism

03:22
OFEV® MOA in IPF
/sg/inflammation/nintedanib/efficacy/largest-prospective-phase-iii-clinical-trial-patients-ssc-ild

SGOFV2023COM||SENSCIS® trial
/sg/inflammation/nintedanib/efficacy/exploratory-analysis-suggests-ofev-may-extend-life-expectancy

Mortality data in IPF
/sg/inflammation/nintedanib/efficacy/ofev-slows-fvc-decline-regardless-baseline-fvc-impairment

OFEV® in IPF patients with FVC ≤50% predicted
/sg/inflammation/nintedanib/efficacy/ofev-significantly-reduces-risk-ae-ipf-pooled-inpulsis-1-and-2

OFEV® and acute IPF exacerbations
/sg/inflammation/nintedanib/efficacy/consistent-treatment-effect-ofev-irrespective-disease-stage

OFEV® across different disease severities
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/vigilance-and-proactivity-are-critical-reducing

SGOFV2023COM||Screening for ILD in your SSc patients
/sg/inflammation/nintedanib/safety/management-ofev-related-diarrhoea

Managing your IPF patients on OFEV®
/sg/inflammation/nintedanib/safety/most-common-gi-related-adverse-events-ofevr-are-mild-moderate

SGOFV2023COM||Managing your SSc-ILD patients on OFEV®
/sg/inflammation/nintedanib/dosage/offer-your-patients-one-capsule-twice-daily

Dosing simplicity with OFEV®
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/regular-screening-critical-ild-can-develop-early

SGOFV2023COM||ILD is the leading cause of mortality in SSc
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/once-lung-function-lost-ipf-it-lost-forever

Lung function decline
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/learn-how-acute-exacerbation-ipf-can-impact

Risk of acute exacerbations